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Abstract
This paper is a study about Philadelphia’s comprehensive user engagement sites (CUESs) as the authors address and examine
issues related to the upcoming implementation of a CUES while seeking solutions for its disputed questions and plans.
Beginning with the federal drug schedules, the authors visit some of the medical and public health issues vis-à-vis safe injection
facilities (SIFs). Insite, a successful Canadian SIF, has been thoroughly researched as it represents a paradigm for which a
Philadelphia CUES can expand upon. Also, the existing criticisms against SIFs are revisited while critically unpackaged and
responded to in favor of the establishment. In the main section, the authors propose the layout and services of the upcoming
CUES, much of which would be in congruent to Vancouver’s Insite. On the other hand, the CUES would be distinct from Insite,
as the authors emphasize, in that it will offer an information center run by individuals in recovery and place additional emphasis
on early education for young healthcare professionals by providing them a platform to work at the site. The paper will also briefly
investigate the implementation of a CUES site under an ethical scope of the Harm Reduction Theory. Lastly, the authors
recommend some strategic plans that the Philadelphia City government may consider employing at this crucial stage.
1. INTRODUCTION
The opioid epidemic in the U.S. is becoming an ever-
increasing problem. Over the last decade, there has been a
significant and steady rise in the number of opioid related
overdoses. There was a 6.2-fold increase in the total number
of deaths involving heroin from 2002-2015 [1]. During
2016, it is reported that 42,249 opioid overdose deaths
occurred in the U.S. which makes an average of 115 opioid
overdose deaths each day. [2] Also, one in every five young
deaths is opioid-related in the U.S. [2]. Locally, Philadelphia
has been one of the cities that has been most affected by the
opioid epidemic. With estimates nearing 1200 lives cut
short, Philadelphia takes its place as the hardest hit city in
the United States [3]. In 2016, 907 deaths were documented
to be caused by drug overdoses in the city. [4] As of May
2017, it is estimated that there are 50,000 people who have
overused prescription opioids and 70,000 heroin users,
which makes a population who use drugs as high as 26,400
[4]. Also, in 2017, 935 cases of secondary conditions arose
due to the sharing of needles [5]. In 2017, it was determined
that drug overdose was the leading cause of death in the
Philadelphia, killing four times as many people as homicides
[4]. Even the AIDS epidemic at its worst fell 200 deaths
short of the number of drug-overdose-related deaths in 2017
[4].
The drug addiction for some is attributed to doctors’
prescribing behaviors while others become addicted because
they found the street drugs as an outlet for their own
personal problems. While heroin, due to its cheap price, still
ranks as the number one drug circulating through the streets,
fentanyl, the Schedule 2 prescription synthetic opioid
painkiller has flooded the illicit market as a viable and far
more lethal alternative to heroin. Therefore, it has become a
social responsibility to work cohesively to combat the
epidemic both immediately as well as realistically.
The National Institute of Health reports that approximately
40-60% of recovering individuals will eventually relapse.
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Some studies even place this number as high as 80%. With
these numbers in mind, it is deemed that the recovery rate is
as low as 20% just for the individuals who seek
rehabilitation [6].  Successful treatment from opioid
dependence involves integration of both behavioral and
pharmacological approaches. Behavioral therapies include
cognitive behavioral and contingency management therapy,
whereas pharmacological therapies include treatment with
methadone, buprenorphine or naltrexone. Regarding
individuals with substance abuse disorder, it is essential to
use a harm reduction approach. Safe injection facilities
(SIFs) fall under the umbrella of harm reduction, as they will
not only provide opioid users with clean needles and
supervision of medical personnel but will also equip the
users with important information regarding detoxification
and rehabilitation programs.
SIFs have been around for many years in Europe and
Canada, and there is a great number of documented studies
that show that the programs have reduced significantly the
harm on individual patients, as well as a community level.
These initiatives have resulted in a tremendous financial
saving when calculating cost savings for averting infections
such as HIV/AIDS, Hepatitis C, and other preventable
diseases and for thwarting overdose-related deaths. Thus,
Philadelphia, along with other major U.S. cities like Seattle,
San Francisco, and New York, are considering introducing
the harm reduction initiative to the city.
Philadelphia, like the other U.S. cities, attempts to follow
Canada’s SIF paradigm rather than the European one due to
similarities in culture and socio-political climate. However,
we recognize oppositions to the initiatives. The arguments
and claims by the opponents are identical everywhere SIFs
are planned due to the same ethical justification for SIFs and
its practical application. Among the various disputes, five
major criticisms can be found against the implementation of
a SIF. That is, SIFs 1) will ultimately fail because the users
are those who not wish to quit to begin with; 2) encourages
drug use and disincentivizes drug cessation because it sends
out the message that drug use is legally tolerable, if not
acceptable, and that drug addiction is medically manageable;
3) promotes drug tourism from outside the community; 4)
causes crime and disorder in the neighborhood; and 5)
abstinence-based programs may work better to fight the
opioid crisis than the harm-reduction programs like SIF.
This paper seeks to mitigate potential concerns surrounding
these claims based on conceptual-psychosocial analysis and
empirical evidences such as statistical data.
Ultimately, the focus of this paper is to help the City of
Philadelphia systematically concretize plans, beyond
piecemeal efforts and discussions, and bring in its first SIF,
comprehensive user engagement sites (CUESs). To
determine the CUES as a viable option for Philadelphia, this
paper is outlined in the following sections. In the section that
immediately follows, medical and public health issues
related to the current opioid addiction vis-à-vis SIFs/CUESs
are addressed. This section explores the medical standards
used by the U.S. federal government to “schedule” opioid
drugs and regulate their use in conjunction with state
government policies. The medical and pharmacological
aspects of heroin, and fentanyl and its analogues because
those substances are what the CUES staff should be most
familiar with. In the next section, we will introduce the
backgrounds and workings of Canada’s SIFs, Insite, which is
thoroughly investigated since a CUES will be modeled after
Insite. In addition, five major criticisms against the
implementation of SIFs/Insite facilities are reviewed. The
third section, the authors propose their visions of CUESs in
terms of its layout and services in detail. The CUES is
congruent to the modeled Insite in addition to placing further
emphasis on the following services: fentanyl screenings,
wound care, Hepatitis-C/HIV screenings, a needle exchange
program, Narcan distribution and education, counseling for
rehabilitation and detoxification done by individuals in
recovery, and early education. In the fourth section, the harm
reduction ideal is introduced as consisting of the practical,
ethical criteria in support of the moral implementation of the
CUES. Lastly, the paper concludes by recommending some
strategic plans that the Philadelphia City government may
consider carrying out the plan to implement the CUES.
2. MEDICAL AND PUBLIC HEALTH ISSUES
2.1. Drug Schedules
Under the Controlled Substances Act, the U.S. federal
government classifies drugs or substances in terms of the
degree of potential abuse which leads to severe
psychological and physiological dependence and of accepted
medical use. Classified into five (5) categories, Schedule 1
drugs are considered to have high potentials for abuse and no
accepted medical use, thereby making the listed drugs
effectively illegal except medical research. “Heroin, lysergic
acid diethylamide (LSD), marijuana (cannabis), 3,4-
methylenedioxymethamphetamine (ecstasy), methaqualone,
and peyote” fall under this list of Schedule I drugs [7].
Drugs in the lower four categories (Schedules 2 to 5) are
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considered to have some medical use but differ in ranking in
potential for abuse (from high to low). For instance,
Schedule 2 drugs, which are “combination products with less
than 15 milligrams of hydrocodone per dosage unit
(Vicodin), cocaine, methamphetamine, methadone,
hydromorphone (Dilaudid), meperidine (Demerol),
oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and
Ritalin” may have some medical use but have a high
potential for abuse related to severe psychological and/or
physical dependence [7]. Meanwhile, Schedule 5 drugs such
as “cough preparations with less than 200 milligrams of
codeine or per 100 milliliters (Robitussin AC), Lomotil,
Motofen, Lyrica, Parepectolin” present the least potential for
abuse [7].
However, despite the federal drug scheduling law, each state
has different policies to control medical and recreational
drug use. From the perspective of drug enforcement, federal
agents focus mainly on trafficking while state agencies make
most arrests for drug possession [8]. But, on the federal
level, the charges brought upon people in possession of
drugs are not strictly conformed to the drug schedules. The
Drug Enforcement Administration (DEA) uses the drug
scheduling as a reference to determine the charges for drug
possession. However, marijuana trafficking is treated less
severely than cocaine trafficking though the former is
Schedule 1 drug while the latter belongs to the Schedule 2
category. The reason that marijuana trafficking is treated less
severely is that many studies suggest that marijuana has
some medical use. But it is hard to deny that the trend
ultimately reflects change of the current cultural-political
climate on marijuana use. As of July 2018, 31 states
(including D.C., and the U.S. territories of Gaum and Puerto
Rico) have legalized medical use of marijuana. Its
recreational use is legal in 9 states including California,
Washington, and Colorado [9]. Furthermore, additional
states are considering the legalization of medical and
recreational use of marijuana. However, apart from
marijuana, both federal and states governments act in unison
in strictly regulating use of Schedule 1 and 2 drugs. Again,
Schedule 1 drugs (except medical marijuana) are effectively
illegal for use except medical research, and Schedule 2 drugs
can be used for medical purposes through physicians’
prescriptions. But so many physicians have legally yet
unethically prescribed their patients Schedule 2 drugs,
fentanyl, oxycodone, Dexedrine, Adderall, etc.
2.2. Heroin
Diacetylmorphine, or more commonly known as heroin, was
first synthesized from morphine in 1800s and sold as a "non-
addictive” morphine subsitute [10]. Like morphine, heroin is
considered a natural drug since it is scored from poppy
plants before it is turned into opium and sold as the
notorious drug. As a Schedule 1 drug, heroin is no longer
used in the medical field today as it is regarded as having no
medical use and fatally dangerous because it causes severe
physical and psychological addictions. Its cheap cost
coupled with high potency makes heroin the drug of choice
for many opioid users, contributing to the worst opioid
epidemic in U.S. history. In 2017 alone, heroin-overdose
death reached over 1,000 in Philadelphia [11].
2.2.1. Pharmacological Facts and Methods of Intake
What makes heroin truly unique is that it is more lipid
soluble than other opioids, meaning that it can rapidly cross
the blood brain barrier and reach high levels to give users
their euphoric effects within seconds [12]. In fact, it crosses
the blood brain barrier 100 times faster than morphine [12].
The effects of heroin can be immediately reversed with
Naloxone, which is an opioid antagonist working to displace
the drug from its opioid receptors. However, the effect of
Naloxone is only temorary. Its use is a stopgap measure
while waiting for EMS. Heroin can be administered different
ways (orally, injected intravenously, snorting, smoke
inhalation, or even as a rectal suppository). When taken
orally, it undergoes an extensive first pass metabolism,
meaning that it is broken down to morphine by the liver and
gut, significantly reducing its euphoric effect. Instead, when
used intravenously, it is profused in the blood and thus
causing its euphoric effects to be far more palpable.
Therefore, the injection is the most popular method for drug
users.
2.2.2. Physical and Psychological Effects and Dangers
Like all opioids, heroin mimics the effects of endogenous
endorphins. It produces the analgesic effects to relieve pain
as well as its desired effect of euphoria. However, its
immediate effects also decrease the invididuals’ respiratory
drive, putting them at risk for overdosing on the drug and
causing death. In addition, the heroin users are also at
significant risks from contracting lung infections such as
pneumonia and tuberculosis due to their poor general health
as well as depression of their respiratory drive. The chronic
use of heroin is particularly dangerous because the brain will
essentially shut down the natural production of endorphins
since the users are receiving them externally via the drug.
Without its intake, the users start to feel withdrawal
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symptoms including depression, diarrhea, cramping, tearing
and excessive sweating. It causes users to feel the need to
resort back to heroin or one of its derivitives to get rid of
those negative feelings.
Injection, compared to the other methods of intake, poses the
greatest risks because it is more potent and fatal. Meanwhile,
when heroin is not injected in a sterile fashion (e.g., through
needle-sharing), the users place themselves at high risks for
infections such as HIV, hepatitis B and C, endocarditis, and
other blood-borne illnesses, all which can be fatal. In fact, in
2016, approximately 9% of newly diagnosed HIV infections
were from people who inject drugs [13]. Making matters
worse, it is nearly impossible to quit heroin, having up to a
90% relapse rate [14]. This is compounded by the fact that
alternatives to heroin that are used to serve as a bridge to
quiting include drugs such as methadone, which are
naturally addictive themselves. In fact, one study in Dublin
found that 91% of opiate-dependent users in Ireland reported
relapse after going through a 6 week treatment program [15].
2.3. Fentanyl and Its Analogues
Fentanyl and its analogues such as carfentanil and sufentanil
are a set of deadly synthetic opioids that are flowing into the
United States at record rates. In fact, it was found that 84%
of opioid-associated deaths in Philadelphia were associated
with fentanyl or one of its derivatives [16]. First synthesized
in 1959, fentanyl entered medical use in 1968 to be used as
an anesthetic and analgesic [11]. Today, it is considered a
Schedule 2 drug and is growing in popularity for both
medical and illicit uses. It is lawful for doctors to prescribe
fentanyl since it is a Schedule 2 drug. However, due to over-
prescription, irresponsible prescribing practices, and
aggressive and misleading marketing of pharmaceutical
companies, physicians and pharmaceutical companies are to
be held accountable for its abuse. Also, combined with their
illicit form of use, fentanyl and its analogues have come
close to heroin in drug abuse.
2.3.1. Fentanyl: Pharmacological Facts and Methods of
Intake
Fentanyl is a synthetic pure μ-opioid available as an injection
in transdermal and transmucosal formulations. Due to its
high lipid solubility and low molecular weight, it rapidly
diffuses across the blood brain barrier compared to
morphine. Like heroin, fentanyl can be smoked, snorted, or
injected. Fentanyl is often cut with much weaker heroin,
making it much more powerful and deadlier than heroin
alone. Its effects can also be countered by Naloxone.
However, fentanyl’s potency may require multiple doses of
Naloxone and possibly even a continuous drip to overcome
the effects of fentanyl. However, it should be noted that
Naloxone is only a temporary measure.
2.3.2. Fentanyl: Physical and Psychological Effects and
Dangers
The effects of the synthetic drug are typical of other opioids
in that it acts on opioid receptors, resulting in analgesia,
sedation, and euphoria. Because of its high lipopholicity, it
approximately 75 to 100 times more potent than natural
opioids like heroin and morphine as it can more easily
penetrate the central nervous system within a matter of
seconds. Though its effects are similar to heroin, fentanyl
causes greater sedation and greater respiratory depression
[11].
2.3.3. Fentanyl Analogues
There has also been a recent rise of the use of fentanyl
analogues. Carfentanil was first synthesized in 1970s and
has been used as a tranquilizer for elephants and other large
animals. It is approximately 10,000 times that of heroin and
morphine and 100 times that of fentanyl [16]. A weaker
substitute for carfentanil is sufentanil, approximately 10 to
20 times less potent than carfentanil which, in turn, is 500 to
1000 times more potent than heroin and morphine. These
analogues are so powerful that just merely coming into
contact with what is equivalent to a few grains of salt can be
fatal [16].
3. INSITE: CANADA’S FIRST SUPERVISED
INJECTION FACILITY
3.1. Insite in Planning
In the mid-late 1990’s, Vancouver’s health authority
declared a public health emergency in response to over 300
fatal overdoses and close to 20% of the local people who
inject drugs (PWID) testing positive for HIV. In response to
the epidemic, the “Cain Report” was developed by a task
group comprising of members from the Provincial Chief
Coroner of British Columbia. After reviewing the success of
SIF implementation in Europe, the group recommended
exploring a SIF as an option to combat the growing opioid
epidemic in Canada.
From the years of 1995 through 2002 a series of
developments ultimately led to the opening of Canada’s first
legally sanctioned SIF. Vancouver’s efforts through
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unsanctioned SIF’s and advocacy for policy change led to
increased public dialogue. In support of SIF, both local
organizations and the City Council of Vancouver developed
the Four Pillar Drug Strategy. The strategy was based on the
ethical-clinical justification of the harm reduction approach,
developed from Western Europe. Officials from Europe with
experience in SIFs met with local PWID, their families,
activists, healthcare professionals, and researchers known as
the Harm Reduction Action Society the result of which a
pilot SIF was introduced [17]. In 2002, the Registered
Nursing Association of British Columbia (RNABC)
supported the supervision of injections as an ethical
obligation, citing potential harms with unsupervised
injections [18]. In 2003, the Portland Hotel Society (PHS)
was working quietly building a SIF in a vacant public
building. Cooperation between PHS and the regional health
authority was established and became the impetus behind the
final push for approval. Soon after, Canada’s first sanctioned
SIF, named “Insite,” was given federal exemption under
Section 56 of the Controlled Drugs and Substances Act
granted by the federal Health Minister.
At its inception, the Insite program faced immediate
oppositions from the newly elected conservative government
then. Disagreements between the PHS and the government
would take the issue to the Supreme Court of Canada. The
government had appealed after the Supreme Court judge
ruled in favor of Insite’s continued operation, but the
Supreme Court justices ruled 9-0 in favor of Insite [19].
Insite is operated by Vancouver Coastal Health (VCH), a
regional health authority which is one of six publicly funded
healthcare organizations within British Columbia. VCH
provides funding, administrators, and clinicians to maintain
Insite while cooperating with the Portland Hotel Society
(PHS) and Community Services Society, a non-profit
organization which furnishes “housing, service, and
advocacy to those poorly served in Vancouver and Victoria,
BC” [20].
3.2. Insite at Work
3.2.1. Statistics
Since its opening in 2003, more than 3.6 million users have
injected at the facility. According to 2017 data, most users
are men with only 28% being women, and 18% of users are
of indigenous ethnicity [21]. Heroin is by far the most
commonly used drug at Insite (64%) though both
methamphetamine (25%) and cocaine (6%) have been
reported [21]. Over the years, a total of 6,440 interventions
for overdoses have occurred at Insite with a total number of
48,798 users who underwent clinical treatment in some form
for their substance abuse disorder. [21] In 2017, there were
2,151 overdose interventions in total; 175,464 visits made by
7,301 different users with an average of 415 visits per day to
the injection room and of 537 needle exchange services per
day; 3,708 other clinical interventions including wound
treatment and pregnancy testing [21]. Concerning the
mortality rate, among residents living within 500 meters of
Insite facilities (70% of Insite users), “overdose deaths
decreased from 253 to 165 per 100 000 person-years (PYs)
and the absolute risk difference was 88 deaths per 100 000
PYs; 1 overdose death was prevented annually for every
1137 users.” [22] [23]
3.2.2. Location
Insite is located in the Downtown Eastside neighborhood of
Vancouver in which a large population of PWID reside.
Throughout the early 1960’s, heroin and crack cocaine
became common substances of abuse in Downtown Eastside.
Commercial real estate was relocated while single-housing
occupancy hotels remained. The changing landscape of the
city prompted an increased concentration of people with
addictions [19]. Still, Downtown Eastside is a dangerous,
impoverished area where a disproportionate number of
residents are Aboriginal people.
3.2.3. Layout and Services
Insite currently serves approximately 800 people each day
with hours from 7:00 am to 3:00 am every day. Users must
be age 19 or older to use the facilities [21]. PWID bring their
own drugs, and Insite staff provide clean needles and
medical supervision. The Insite facility in Vancouver houses
12-seat injection rooms with booths where the users can
inject their own drugs using clean syringes, cookers, filters,
water, and tourniquets supplied by the Insite staff including
nurses. The staff monitors all users for signs of any overdose
and intervenes if the overdose occurs. The nursing staff also
provides other health services including wound care,
immunizations, and pregnancy tests. After injecting, the
users can move to a post-injection room with refreshments
and interact with the staff in a safe environment.
The facility also provides recovery/detoxification services in
the upstairs of the building which is a place called “Onsite.”
Onsite is open 24 hours, 7 days a week for anyone age 19 or
older, and staffed by mental health professionals, counseling
therapists, nurses, and physicians. Onsite features 12 rooms
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with private bathrooms while offering a variety of recovery
resources for the Insite users. The patients are referred from
Insite itself as well as from some other hospitals. During the
2017-2018 fiscal year, a total of 443 users accessed Onsite
services with 11 days being the average length of stay.
Onsite staff actively encourage the patients to connect with
their families and obtain employment.
On the third floor of the Insite building is transitional
recovery housing for a step-down program. The users can
join the program after they have been treated at Onsite;
during their stay in the housing, the users can access further
treatment programs and community supports such as
information about further housing arrangements.
The administrators at Insite stress that recovery can only be
successful as the staff and users build trust with each other.
Thus, they make sure that the Insite staff is trained to create
“respectful, tolerant relationships with individuals who are
chronically marginalized and dehumanized” so that the staff
can help users to move forward with their recovery by
seeking detoxification and c services [24]. They boast that
the “Insite staff are experts at listening, and, through
listening to participants’ stories and needs, help connect
them to other services including wound treatment, housing
needs and referral to treatment services such as withdrawal
management and opiate replacement”[24].
3.3.Discussion
3.3.1. Harms Reduced/Benefits Reaped: Documented Data
There has been a great amount of research and surveys
evaluating the efficacy of Insite since its opening in 2003.
There have been a 35% drop in overdose deaths since 2003
in the area surrounding Insite (compared with a 9% decrease
throughout Vancouver), reductions in public drug use and
discarded syringes, and shifting the burden from emergency
medical services through on-site overdose management [25]
[26] [27]. A study by the British Columbia Center for
Excellence in HIV/AIDS finds that people who use safe
injection sites are 30% more likely to enter detox programs
and 70% less likely to share needles [27]. Insite has been
found cost-effective due to averted medical expenses
through clean needle exchange and cutting down HIV-
related medical expenses [28][29][30]. Financially, it is also
projected to produce even larger return on investments
through the propagation of safe injection practices [28].
These analyses have also been utilized as a tool in evaluating
the prospects of opening additional SIFs in Ottawa and
Toronto [31] [32].
Nevertheless, there was considerable resistance to the
implementation of SIFs like Insite, and the opponents have
shown many arguments and claims against the
implementation of SIFs. In the following, we introduce five
major criticisms to which we will show our critical
responses [23].
3.3.2. First, the Insite Program Will Ultimately Fail Because
PWID Do Not Want to Quit to Begin with.
There is a view shared among the opponents of SIFs that the
Insite program will eventually fail because the addicted
people who use the facility do not want to quit the behavior
to begin with. In other words, the drug users are happily high
all the way to their own demise, so the best thing for the
society to do is just not to bother them. To reply, first, the
documented data above indicating the efficacy of Insite
program already confronts the criticism. The Insite program
is no longer considered a pilot study but rather an established
program. However, the critics can still argue that in a long-
term projection the SIFs will eventually fail due to the
aforementioned reason. Thus, we engage in a conceptual-
psychological analysis to show errors in the claim.
The view that the addicted people do not wish to stop the
drug habit in the first place presupposes the assumption
either 1) that the PWID are completely void of any desire to
quit the drug habit, or 2) that the PWID evaluate their desire
to stay addicted so positively that the desire to quit is an
insignificant element in their decision-making process.
Confining the discussion to the group where a strong form of
drug addiction is already set in like the Insite users, the
former possibility is false because it is a plain fact that the
addicted people have two conflicting desires: 1) the desire to
stay addicted, and 2) the desire for capability of executing
the will to do away with the habit and start a normal life,
which can be equivalent to the desire to quit using drugs.
That the PWID evaluate their desire to stay addicted so
positively that the desire to quit is an insignificant element in
their decision-making process is also repudiated because, if
the addicted people’s understanding and perception about
their addiction is so affirmative that they prefer to remain in
addiction, it would mean that they enjoy not only the drug-
induced euphoria but also the concomitant low quality of life
which would be exacerbated day by day with chronic
illnesses, financial difficulty, emotional instability, and
social isolation. However, it is very difficult to believe that
anyone would enjoy such a lifestyle that people ordinarily
regard as a great disvalue. In fact, empirical evidences are in
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disagreement with the claim that the addicted people enjoy
the lifestyle of addiction. There are numerous stories of
addicted people out there. For some, the lifestyle of
homelessness and poverty caused them to rely on drugs.
Some began using drugs to overcome physical trauma or
sexual abuse or neglect while others started to seek street
drugs after discharged from the hospital where they were on
opioid painkillers prescribed by their doctors. Witnessing all
these terrifying, emotional stories, it is difficult to think that
PWID are enjoying the life of misery. 
In fact, the position that the SIF program will eventually fail
because PWID do not wish to change is fundamentally
linked with the society’s stereotype perception about PWID.
Because so many PWID possess concomitant diseases such
as HIV and HCV, they are often perceived as people who
gave up on themselves. But this stigmatization is directly
against the purpose of medicine because medicine is a
practice committed to nonmaleficence (do-no-harm) and
beneficence (strive-to-help) regardless of patient status. But
in most cases the social stigmatization is derived from lack
of knowledge about the targeted group. In our case, many
people do not have the knowledge about who the Insite users
are, how they have gotten there, and how specifically SIFs
can help them. Thus, education, particularly community
education, seems a solution to overcome this negative
perception [33].
3.3.3. Second, Insite Encourages Drug Use and
Disincentivizes Drug Cessation Because It Sends out the
Message that Drug Use is Legally Tolerable, If Not
Acceptable, and that Drug Addiction is Medically
Manageable.
Another popular criticism by the opponents of SIFs is that
Insite promotes drug use and discourages drug cessation
because its operation gives the community the message that
drug use is legally tolerable, if not acceptable, and that drug
addiction is medically manageable. And its extended
variation can be that minors will be introduced to drug use
believing that the Insite program is a legal endorsement to
use drugs and/or is a medical safeguard to manage drug
addiction.
This view has some important points to consider. It is true
that the Insite facility is a legal safe-haven for the users and
that the medical professionals at the facility are there to help
PWID to manage the medical symptoms associated with the
drug addiction. However, the message that Insite gives to the
community is neither that drug use is legally tolerant
everywhere because the narcotic law is not enforced de facto
due to a great social acceptance, nor that drug use/addiction
is a medically manageable practice/symptom due to a recent
medical advance. If and only if these are true, it can be said
that drug use is promoted and that drug cessation is
disincentivized by Insite. Furthermore, if anyone
understands the idea behind the Insite program this way, this
is a rather strange understanding about the issue because
ordinary adult members of society understand that drug
addiction is highly difficult to overcome without
professional help and thus that the addicted people will
inject the drugs illegally anyway. That is why the Insite
offers a legal safe-haven where they can use their own drugs
so that medical professionals can encourage them to commit
themselves to rehabilitation while providing the managed
medical care before it is too late (overdose death). 
Statistical evidences are in favor of this defense. According
to the 2000-2006 data published by McCreary Centre
Society, a non-governmental, not-for-profit center whose
work is focused on promoting health of the youth in the
province of British Columbia, the use of illicit drugs such as
heroin, amphetamine, crystal meth, and prescription opioid
drugs obtained without prescription declined overall in both
Vancouver and Victoria, the two cities of BC, where Insite
serves PWID [30], which means that people are not
motivated to use drugs because of the Insite program.
Meanwhile, the McCleary Centre Society report includes
that the rates of injecting an illegal drug increased by 14% in
the province of British Columbia [34] One way of
interpreting the data is that the increase is due to the
population increase within the province. Vancouver’s
population increased by 57,831 according to the census data
from 2001 to 2011 [35]. This data affirms the validity of our
view because it would mean that the illegal drug use
decreased in the communities that Insite serve while it
increased in the rest of the communities despite the increase
of the general population of BC.
Also, according to a comparative study conducted to
examine the community drug use pattern within 3 years
before and after the opening of Insite, there was no a
significant increase in relapses back into injection drug use
(17% before, 20% after), nor was there a significant decrease
in people ceasing their drug use altogether (17% before, 15%
after) [35]. Another study surveyed a group of 1065 PWID
that utilized Insite during its first two years of operation to
gather information on their first experience with injection
drug use. Of this group, only 1 person reported that their first
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injection was done at Insite. When extrapolated to the entire
population that utilizes Insite (approximately 5000 people at
that time), it was estimated that only 5 people may have
initiated injection inside the facility [35]. In addition, 14
individuals reported having initiated injection drug use after
the opening of Insite, and none of them reported having done
so within the facility [35]. These findings indicate that, at
least initially, the vast majority of Insite users were long-
time injection drug users, with no evidence to support
increased rates of first time injection drug use.  In addition,
several studies show that Insite users are more likely to
initiate detoxification and addiction treatment. A 2007 study
comparing detoxification service use among 1031 PWID
before and after Insite opened found a statistically significant
increase of 30% in utilization of detoxification services [37].
Initiation of detoxification services were independently
associated with initiation of addiction treatment and overall
decreased utilization of the SIFs [37]. And a study using data
from 2010 to 2012 among 1316 PWID showed that 147
individuals (11.2%) reported enrolling in detoxification
services at least once during the study period [38].
It is admitted that much of the data comes from the studies
were conducted in the first few years of Insite’s operations.
Thus, more updated research is needed to support
conclusively the idea that SIFs like Insite do not increase
injection drug abuse but help PWID move towards cessation.
Nevertheless, we believe that, given all the reasons so far, it
is less likely to be expected that brand-new studies will show
results otherwise.
Lastly, to respond to the extended version of the criticism
that minors would feel motivated to use drugs because of
Insite, it is hard to know whether this would be true or false
because it is difficult to collect and verify the validity of the
data. It is not easy to develop a robust survey to inquire if the
minors injecting drugs were introduced primarily because
they perceived the Insite program as the legal and medical
support for the drug use. Even if such data was obtained, it is
hard to accept the teenagers’ answers as credible as they are
considered minors. However, if some of the drug-addicted
minors, in their susceptible minds, began using drugs
believing that the Insite program was the legal and medical
greenlight for drug use and addiction, the burden of
responsibility should be on the public relations (PR)
professionals of Insite, not the Insite’s operation itself. For
example, it is reasonable to think that minors start smoking
cigarettes not because of the local convenient stores selling
cigarettes but because of tobacco companies’ deceptive
marketing to teens. Note that minors are not allowed to use
Insite (the minimum age for Insite users are 19), as they
cannot buy cigarettes from convenient stores. In the end, it is
how we advertise the Insite program to the community that
determines whether the minors misinterpret the Insite’s
operation or not. Successful PR, media strategy, and creative
advertising plans are needed to send the right message to the
members of the community including the minors. However,
above all, we stress that community education is the best
marketing. This is the reason that the Philadelphia’s CUES
program, as we propose, must be equipped with the
community education project which we will address later in
detail.
3.3.4. Third, Insite Promotes Drug Tourism from Outside the
Community.
Another popular criticism raised is that Insite promotes drug
tourism. To respond immediately, although there have been
no recent studies, the data obtained from the first few years
do not support the claim, for, as shown above, the vast
majority of PWID users are residents in the area. In addition,
it is difficult to believe that people travel a long distance to
use the Insite facility located in a place like Downtown
Eastside. Downtown Eastside is a dangerous, impoverished
area where a disproportionate number of residents are
Aboriginal people. Thus, it is highly unlikely that outsiders
come to Downtown Eastside for drug tourism. Note that the
proposed injection site in Philadelphia, Kensington, is
similar to Downtown Eastside in this regard.
3.3.5. Fourth, Insite Causes Crime and Disorder in the
Neighborhood.
The opponents of SIFs say that Insite causes crime and
disorder in the neighborhood where Insite facilities are
located. At the opening of Insite, they had predicted that
general crime, including drug sales, and motor vehicle
collisions (due to impairment) would increase as a direct
result of the opening of a SIF. By contrast, however, public
order has been shown to improve in the area around Insite,
with one study showing decreased public drug use and less
discarded syringes in the 12-week period following the
opening of the facility [39]. Another study specifically
examined the impact of Insite on crime in Vancouver, but
neither an increase nor a decrease was reported in drug-
trafficking or assaults/robbery in the year prior to the
opening of the site versus the year after. Rather, a decrease
in vehicle break-ins and theft was observed [39].
Nevertheless, while the information so far offers
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counterevidence to the criticism that SIFs promote crime and
social disorder, data from more recent years would help to
solidify this assertion. However, we argue that a well-
organized police patrol and security enforcement in the area
will solve this problem.
In the Philadelphia context, PWID will not be wary to use a
CUES because of the perspicuous presence of the police and
security enforcement. PWID will know that they will not get
arrested for using the facility, as the city government has
campaigned about the legal immunity for those using the
CUES. It is expected that the police and security officers
will go around to talk to the PWID while making sure of the
safety of the area.
3.3.6. Last, Abstinence-Based Programs May Work Better to
Fight the Opioid Crisis Than the Harm-Reduction Programs
like Insite.
The last criticism we introduce is that to fight the opioid
crisis, abstinence-based programs, assisted variations of
“cold-turkey,” will be as much effective as the harm
reduction programs like Insite [40]. The critics add that the
merit for adopting the abstinence-based program will save a
lot of public funds. It is true that Opioid Replacement
Therapy (ORT), a kind of abstinence-based approach, has
been found to be particularly effective in reducing relapse
events and decreasing mortality in former drug addicts [41].
[42] Also, the efficacy of a prize-based or motivational
incentive, which is another kind of abstinence-based
approach, can also be addressed to support the critics’
argument [41] [42].
We reply, however, that both programs above show that the
abstinence-based programs are efficacious in improving the
conditions of opioid drug abusers only in an outpatient
setting [43] [44]. However, the abstinence-based programs
do not voluntarily attract most drug users as well as fail to
recognize the recovery-status of individuals on medication-
assisted therapy [45] [46]. Also, we suspect that the
outpatient drug abusers are those whose physical and
psychological conditions are not as severely impaired as
most of the Insite users.
Ultimately, it is unknown whether the abstinence-based
program may work better than the harm-reduction program
because no studies or pilot programs have been conducted in
a community setting. But it is important to understand that,
at a deeper level, the advocates for the two different
approaches come from respectively different philosophical
anthropological views. The supporters for abstinence-based
program assume that rational human will is the ultimate
decision-maker and thus that all human decisions are the
products of our rational deliberations even though they may
not appear to be. As a result, the addiction is overcome only
when the individual rationally deliberates over his/her own
situations and problems and decides to take the steps to
control it. Accordingly, the only effective external aid is to
assist his/her rational will with some psychological boost
such as prize-based or motivational stimuli that the
abstinence-based programs may provide.
On the other hand, the anthropological presupposition
behind the harm-reduction approach is that, although we are
creatures with rational willpowers, a vast number of our
decisions are made by unjustifiable desires. In certain
circumstances, desires impair our capacity for rational
decisions. The drug addiction is such an occasion because it
is the mental state where the desire to use drug prevails over
or controls one’s rational ability to stop the behavior. Thus,
the best we can do is to entice the addicted people into the
path where their distorted mental state can be restored
without punishing them, which is what the harm-reduction
strategy is all about.
In sum, the question if the abstinence-based program may
work better than the harm-reduction program or vice versa
depends on which of the two philosophical anthropologies
that we fundamentally subscribe to. In addition, as
mentioned above, since there has not been any major
investment to institute the abstinence-based programs or
research studies in a community-setting, there is no way to
tell which program is more effective to fight the opioid
crisis. However, in philosophical bioethics literature, there
have been strong arguments that addicted people, including
PWID and tobacco smokers, should be treated as those who
lost rational willpower and thus that strong governmental
and organizational interventions are needed to help those
suffering the loss [47] [48].
4. COMPREHENSIVE USER ENGAGEMENT
SITES (CUES) IN PHILADELPHIA
In Philadelphia, drug overdose deaths rose by more than one
third, up to 1,217 last year (2017). There is no doubt that the
opioid epidemic is worsening in the city. The City of
Philadelphia has been looking into ways of combating this
crisis, the solutions for which must be as multifaceted and
dynamic as the complexity of its problems. The mayor of the
city, Jim Kenney, has gathered a group of people and created
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the Task Force to Combat the Opioid Epidemic whose
mission is to analyze the situations, collect data, and create a
list of possible solutions to help combat the epidemic.
Among the recommendations are education programs,
treatment availability, screenings, housing for recovery and a
few others. Suggestion #13 calls for the opening of the first
“Comprehensive User Engagement Sites” (CUES), which
entails the opening of a safe injection site where people can
come and safely inject drugs under the supervision of trained
healthcare professionals. Modeling after the success of
Vancouver’s Insite, these facilities would offer clean
needles, naloxone in the event of an overdose, education on
how to safely use along with the dangers behind drug use,
and most importantly, avenues into recovery [49] [50].
4.2. CUES in Planning: Analysis
Mayor Jim Kenney and District Attorney, Larry Krasner, are
the two most important proponents for CUES in
Philadelphia. The mayor and district attorney assert that the
opioid pandemic, other than its direct tolls such as death and
related public health issues, has increased violence and
homelessness in Philadelphia and has placed undue stress on
the city’s EMS system. Citing the failed “War on Drugs” in
response to Philadelphia’s crack epidemic, the duo wants to
shift from the criminalization of drug use and its
enforcement, to treating addiction.  Instead of incarceration,
more avenues to treatment and recovery will be offered to
those struggling with addiction. Drug use and addiction will
be treated as a health issue, not a legal one. Therefore,
Kenney and Krasner hope that the implementation of CUES
will provide a direct link to treatment, distribute naloxone,
save lives, and keep PWID alive until they enter recovery
[49]. In support of CUES, Philadelphia Health
Commissioner, Thomas Farley, also said in January 2018:
“We have an obligation to do everything we can to prevent
those people from dying” [51]. In addition, Philadelphia
Police Commissioner, Richard Ross Jr., a staunch opponent
to the CUES initially, told that he was open to the idea of the
facilities.  In sum, there seems to be an agreement among
city officials.
However, due to the novelty of this undertaking, state
legislatures are not so sure about the plan. Being the first of
its kind in the U.S., political and legal backlash seem
inevitable. For example, Pennsylvania Governor, Tom Wolf,
believes these sites present significant legal and public
health concerns [51]. He claims that he would not stand in
the way of Philadelphia, should they decide to open CUES
[52]. Further complicating matters, US Attorney General,
Jeff Sessions, is an outspoken opponent of the CUES,
favoring a “war on drugs” style approach to combating the
epidemic [53]. In a letter released December 2017 from the
Vermont District of the US Attorney’s Office, a proposal for
the safe injection sites was condemned, asserting that these
sites would only exasperate the opioid problem,
undermining work in recent years from local law
enforcement to curb this blight.  Fears were expressed over
the “normalization” of heroin and other narcotic use, which
in turn would lead to children to think heroin use is not only
permissible, but also that the government will help you do
it.  The Vermont US Attorney’s Office further asserts that
the CUES would only fuel the illegal drug market, and that
court-mandated rehabilitation would be more effective than
implementation of a CUES.  However, perhaps the biggest
blow would be the assertion that both users and staff at the
CUESs would be subject to criminal prosecution [50]. The
Controlled Substances Act Section 856 states:
Except as authorized by this subchapter, it
shall be unlawful to— (1) knowingly open,
lease, rent, use, or maintain any place,
whether permanently or temporarily, for the
purpose of manufacturing, distributing, or
using any controlled substance; (2) manage or
control any place, whether permanently or
temporarily, either as an owner, lessee, agent,
employee, occupant, or mortgagee, and
knowingly and intentionally rent, lease, profit
from, or make available for use, with or
without compensation, the place for the
purpose of unlawfully manufacturing, storing,
distributing, or using a controlled substance
[55].
Falling under the “Crack House Statute” (21 USC §856), it
is illegal to operate a facility in which controlled substances
are manufactured, distributed, or used.  Violators are subject
to a felony charge.  The DEA has echoed similar sentiments
claiming that anyone operating or using these sites would be
subject to criminal prosecution at the federal level [56]. On
the other hand, the Surgeon General, Jerome Adams, has
advocated for widespread use of naloxone, encouraging
individuals who know or may come into contact with
someone who uses opioids, to carry the lifesaving drug [57].
However, beyond this statement, little tangible progress has
been made at a national or federal level.  Additionally, the
letter released by the Vermont District of the US Attorney’s
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Office relies on anecdotal and circumstantial evidence as
well as conjecture, to play on fears and concerns raised
regarding the implementation of the CUES.
Nevertheless, the Crack House Statute (21 USC §856) seems
to play the biggest role in the prohibition of these sites.  As
previously stated, this statute prevents the operation of a site
in which controlled substances like heroin are manufactured,
distributed, or used.  While the CUES do not manufacture or
distribute heroin, the use of the drug does occur under the
supervision of trained healthcare professionals, the fact of
which makes the users and staff at the sites vulnerable to
criminal prosecution.   One alternative might be the use of
mobile or portable CUES sites. This could be a way of
working around the Crack House Statute. Moreover, due to
the current legal status of such a site, it would be difficult, if
not impossible, to obtain the necessary insurance coverage
and zoning permits. 
However, a case can be made in favor of a CUES for it can
be argued that the establishment and operation of SIFs are
legally justified by reference to necessary defense given that
they satisfy the following 6 criteria: 1) The criminal action
was taken to avoid a grave harm; 2) The harm to be avoided
was imminent; 3) There was no available legal alternative;
4) The harm to be avoided was greater than the harm caused
by the act; 5) It was reasonable for the actor to believe that
his/her criminal act would be successful in averting the
threatened harm; 6) There was no apparent legislative intent
to preclude the use of the defense in the situation in question.
Taking a CUES into the context of preventing overdose-
related deaths, the defense of necessity could be invoked to
protect both staff and users from legal repercussions.  One of
the reasons that CUESs are being implemented is to prevent
overdose related deaths.  With the rise of fentanyl and its
analogues being used to cut down heroin, the chance of
overdosing has skyrocketed, putting both users and
healthcare professionals in a very precarious situation, as
overdoses are now more imminent.  While treatment
programs may be cited as an alternative to the CUES, it is
not a viable option as many individuals would be unable to
cover the cost of treatment, especially without insurance
coverage.  Lastly, allowing PWID to utilize a CUES under
the supervision of trained healthcare professionals outweighs
allowing that same PWID to overdose on the street or in a
setting in which naloxone is not available.
While navigating the complexity of the legal system to allow
for the creation of CUES is beyond the scope of this paper,
these are some issues that ought to be brought to light.  We
have reached a point in which Philadelphia’s opioid crisis
only grows worse.  To allow every proposed solution to be
caught up in political debate or bureaucratic red tape is
essentially to sit back and allow this crisis to grow worse.
4.3. Proposed Description of a CUES
4.3.1. Location
In order to make the safe injection sites as successful as
possible, location becomes a pivotal factor.  While use of
heroin and other drugs is rampant around the city, it is
heavily concentrated in the neighborhood of Kensington.
What was once a thriving neighborhood for working class
immigrants has become a mecca of drug dealing, coined “an
open-air drug market” [58]. In the second half of the
twentieth century, Kensington was plagued by racially
motivated violence, gang violence, and significant amounts
of drug trafficking.  Sales of drugs like amphetamines,
crack-cocaine, and more recently, opioids like heroin have
become the livelihood of many individuals residing in the
area.  Kensington is so notorious for its drug sales that
people from New Jersey and Delaware can even be found
routinely stopping by to purchase their drug of choice.
 Furthermore, homelessness has been an increasing issue as
the opioid epidemic persists [58]. Alfred Lubrano, reporter
of the Philadelphia Inquirer, and long-time resident in
Philadelphia, calls Kensington a “Bermuda Triangle” in
which the addicted people come to buy drugs, but somehow
never seem to leave [58]. Given the state of poverty,
homelessness, and rampant drug use in Kensington, it would
make the perfect pilot location for a safe injection site in
Philadelphia, and by extension, the United States.




Logistically speaking, Philadelphia’s CUES will be laid out
in a similar format to that of Vancouver’s Insite.  The CUES
will have a reception area in which PWID will be given a
card with an anonymous identification number.  In addition
to the individual’s anonymous identification number, the
card will contain the address and phone number of the
facility, and the phone numbers of counseling and
rehabilitation programs as well as emergency services in the
event of an overdose. The staff and PWID should be
reminded that the CUES User ID card does not contain the
user’s personal information. Rather, the card is to give the
users information about the facility and where to contact
when emergent situations arise and to collect data to see
whether the CUES is efficient in serving the users.
At registration, a PWID will be required to given basic
information such as how he or she heard about the site, age,
gender, ethnicity, and whether the PWID is interested in
rehabilitation, psychiatric services, wound care, and clean
needle exchange and additional services later addressed in
the paper. This ID card will allow the individual to swipe in
an out of the facility so that the facility’s traffic can be
monitored.  If a user does not have a clean needle, one will
be provided. At this point, it is pertinent to emphasize that
the CUES does not provide the drugs for users to inject.
 PWID must bring their own drugs for use.  Purity testing
kits will be made available for those who wish to test if their
drugs have been laced with substances like fentanyl.            
After reception, the CUES will have a large room with
numerous benches at which PWID can safely inject under
the supervision of trained healthcare professionals. PWID
will be provided with the sterilized supplies or kit needed for
substance-use such as syringes, disposable cookers, matches,
bottled water, and tourniquet. Spaces at the benches will be
partitioned off to create a semi-private space for each
individual (See Figure 1).  Each bench will have a box in
which dirty needles can be safely disposed.  Should an
overdose occur, trained medical professionals will be
available to administer naloxone to reverse the overdose. 
Medical students will also be available to care for wounds
that result from prolonged IV drug use. Oxygen supplies will
be provided if needed.
The injection area is followed by a lounge area in which
PWID can briefly relax for a designated amount of time (30
minutes). It will be not difficult to gauge if anyone is
receptive to the conversation on recovery. Thus, if anyone
seems open to the conversation, the time restriction will be
set aside as the staff engages in the communication process.
It is at this point that educational materials, counseling, and
rehabilitation programs will be offered to PWID.  The goal
here is for those staffing the site to build relationships with
the PWID from the community.  Hopefully, the lounge can
be an area that facilitates conversations about rehabilitation
and treatment for PWID.
 
4.3.3.Services
Due to the effectiveness of Insite in Vancouver, this article
seeks to consider CUES as a viable option in response to the
severity of the opioid crisis in Philadelphia. In terms of
services to be offered, the CUES would be congruent to
Vancouver's Insite. But the CUES that this paper suggests
incorporates additional services, some of which had not been
included in Canada’s Insite, namely, more involvement of
people in recovery and places a particular emphasis on early
education for new and future healthcare professionals. As a
result, the following services are to be provided: fentanyl
screenings, wound care, Hepatitis-C/HIV screenings, a
needle exchange program, Narcan distribution and
education, counseling for rehabilitation and detoxification
done by individuals in recovery, and early education.
Fentanyl Screenings. Fentanyl has become a potent
adversary in the Philadelphia crisis. Sixty-four percent of
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fatal overdoses in the Philadelphia County can be attributed
to fentanyl [55]. With overdoses averaging 800 per year, the
number continues to skyrocket. However, the majority of
PWIDs are unaware that substances that they use are laced
with fentanyl [55]. Therefore, the CUES facility would offer
fentanyl screenings. The use of fentanyl screenings has been
found to change behavior amongst people who inject drugs.
Johns Hopkins and Brown Universities conducted a pilot
study investigating the impact of fentanyl testing with
PWIDs. Using a simple $1 testing strip dipped in the drugs
mixed with water, the study has shown that people who
received positive fentanyl results tend to 1) use less, 2) inject
with someone around and/or 3) to use more slowly. [60]
Upon learning fentanyl was laced in the drugs acquired,
PWIDs became more attuned to severity of their
circumstances and became cautious. As individuals with
opioid use disorder, PWIDs proceeded to inject at their own
risks but were more cognizant of their safety. Therefore,
offering fentanyl testing kits in a CUES would be beneficial
in allowing PWIDs to become more conscious to their
present reality and potentially seek assistance in
rehabilitation and detoxification.
Wound Care. Wound care would be another sector within
the compartmentalized process of a supervised injection
facility as described in Insite. Compounded with the increase
blood-borne diseases, other infections arise as a result from
injecting intramuscularly and subcutaneously with unsterile
needles. Many of these conditions are primarily bacterial
infections: staphylococcus infections, abscesses, cellulitis,
necrotizing fasciitis, botulism, tetanus, and septic
thrombophlebitis [61]. Lacerations and other wounds can be
inflicted from the needle itself due to improper technique.
Therefore, the CUES would have a wound care service
staffed by healthcare personnel such as a physician assistant,
nurse practitioner or students in healthcare education to
provide immediate care for the wounds at the site, which
could minimize the spread and progression of secondary
infections. Treating wounds and infections promptly could
reduce the future healthcare costs further since the estimated
annual savings due to the CUES will range from $1,512,356
to $1,868,205. [8] Additionally, the integration of wound
care services with medical education provides an
opportunity for students to gain practical medical
experience. The wound care service also proactively
addresses the systemic issue within the healthcare system by
allowing future healthcare personnel witness the first-hand
effects of opioid usage within marginalized populations.
Hepatitis-C/HIV Screenings. Hepatitis C virus (HCV) and
human immunodeficiency virus (HIV) infections are the
most prevalent blood-borne diseases that arise from opioid
injections. In 2015, 60% of acute HCV cases in Philadelphia
reported of having injected drugs [8]. Acute hepatitis C lasts
a short time and occurs within six months of infection yet
remains asymptomatic [62]. Nevertheless, 75-85% of
infected cases become chronic through which the virus
remains “silent” for decades yet still attacks the body.
Prolonged exposure to the hepatitis C virus infection can
lead to liver cirrhosis, jaundice, fatigue, fever and muscle
aches. Liver cirrhosis often leads to liver failure or even
cancer. By the time liver cirrhosis is discovered, treatments
entail a 12-week antiviral regimen that ranges from $63,000
to $94,500 per person affected [63]. In 2016, a total of 2846
individuals have reportedly been diagnosed with hepatitis C
in Philadelphia alone [64]. Additionally, 19,113 individuals
had been diagnosed with HIV in 2016, a percentage of
which can be attributed to blood borne infections from
needles [65]. In 2017, 30 new HIV-diagnosed cases were
found among the PWID population [8]. The human
immunodeficiency virus (HIV) infects the body’s CD4 cells
(T cells) that help the immune system fight off infections. If
untreated, the reduction of CD4 cells can lead to further
susceptibility to secondary infections or cancers which
eventually results in the acquired immune deficiency
syndrome (AIDS) [66]. No effective cure currently exists,
but there are treatment plans which reduce the HIV viral
load. The average cost of one drug regimen is $28,688.
According to the CDC, the cost for one treatment over a
lifetime for an HIV infection is estimated at $379,668 per
individual [67]. More often than not, HIV and HCV are
coinfections amongst PWIDs whom are less likely to afford
health insurance. As a result, PWIDs have a tendency to seek
emergency medical attention once the symptoms have
progressed to latent stages, costing healthcare systems.
Therefore, this article proposes to offer HIV/Hep-C
screenings to the CUES.  Each comes with its own OraQuick
Rapid test that detects antibodies for the respective viruses
via a simple fingerstick with results in just 30 minutes. [68]
Offering HIV/Hep-C screenings serves as a proactive means
for both PWIDs and healthcare systems by encouraging
PWIDs to seek treatment early and possibly guide them
further rehabilitative care because it provides a space and
opportunity to be able to test for HIV and HCV infections
which could lead to the overall reduction in healthcare costs.
A Needle Exchange Program. The Syringe Exchange
Program, also referred to as the needle exchange program,
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was instituted in Philadelphia in 1992 in attempt to reduce
the number of blood-borne diseases such HIV caused by the
reuse and sharing unclean needles amongst people who
inject drugs. At that time, 46% of HIV diagnoses had a
strong correlation amongst PWID [69]. The program was
created through which unclean needles could be exchanged
for sterile ones with the provision of education of risks and
implications regarding the sharing of needles. Prevention
Point had thus become the largest and only city-sanctioned
needle exchange program in Philadelphia [70]. Maurer and
her colleagues examined the effectiveness of the needle
exchange program over the span of 15 years between 1999
and 2014 and found that the needle exchange program had
reduced the number of HIV transmission instances via
needle sharing from 46% in 1992, 22.2% in 2006, 11.1% in
2009, and 5.4% in 2014 [69]. The number of new registrants
per year had declined as well from 2168 in 1999 to 1295 in
2014 [69]. Nevertheless, the opioid crisis remains prevalent
in Philadelphia today. Maurer and her team note that, even
though the number of new registrants per year has decreased,
PWID have been utilizing the needle exchanges more than in
the past, especially within the younger generation [69].
Therefore, the conjunction of the CUES with a needle
exchange program offers sterile needles that may further
reduce the transmission of blood-borne diseases while also
providing a space that gives education about the risks
surrounding opioid usage and offers various opportunities
and support that could potentially guide participants into
rehabilitation.  It is important to emphasize that the needle
exchange program would be paired with the CUES as
opposed to needle distribution. The needle exchange
program with the CUES would also serve as a means to help
clean up the area of needles to prevent wounds and
infections caused by unsterile needles.
Narcan Distribution and Education. The partnership of the
educative Narcan distribution with a CUES could be
considered as an attempt to reduce the number of fatal
overdoses in Philadelphia. Narcan is the intranasal form of
naloxone. Naloxone is an opioid antagonist that acts on the
central nervous system to reverse respiratory depression, the
main cause of overdose deaths [71]. Naloxone can enact its
effects within 5 minutes upon administration. The Surgeon
General, Jerome Adams, made a statement in April 2018
urging Americans to carry naloxone:
For patients currently taking high doses of opioids as
prescribed for pain, individuals misusing prescription
opioids, individuals using illicit opioids such as heroin or
fentanyl, health care practitioners, family and friends of
people who have an opioid use disorder, and community
members who come into contact with people at risk for
opioid overdose, knowing how use naloxone and keeping it
within reach can save a life [57].
Moreover, Pennsylvania Act 139, known as “David’s Law”,
provides first responders, friends and families access to
naloxone in hopes to lead an individual toward the substance
abuse treatment that they need [71]. The Good Samaritan
Provision falls under Act 139 to encourage friends and loved
ones to seek emergency medical services upon witnessing an
overdose [72]. In February 2018, Independence Blue Cross
(IBX) announced to make naloxone available to its
subscribers free of charge [73]. IBX will grant subscribers
up to six syringes of naloxone every 30 days effective March
1 [73]. Prevention Point currently distributes Narcan kits and
provides training [70]. Given the federal, state, and
insurance involvement, the distribution of Narcan
complemented with education and training to CUES
participants serves as both a precautionary means of saving
themselves from overdosing and preventing others from
fatally overdosing. Narcan distribution further encourages
PWIDS to recognize and seek help. The use of Narcan can
further reduce the current Philadelphia healthcare cost of
$92,408 per hospitalization with an average length of stay of
7-10 days attributed to overdose [8].
Counseling for Rehabilitation and Detoxification Done by
Individuals in Recovery. The information center can provide
avenues that can connect participants to different resources.
While healthcare personnel will be available to offer their
expertise regarding health, nutrition, and safety, the
information center would primarily be run by people in
recovery. Having one-to-one interactions with people in
recovery facilitate interpersonal relationships to help guide
PWID to other resources available to them. For some, the
information center could be their only exposure to the
various possibilities and opportunities that can be offered to
them such has rehabilitation, detoxification, medication-
assisted therapies, grooming services, counseling and more.
The CUES may serve as a mediator for someone undergoing
the journey through rehabilitation by being the “half-way”
point, which could prevent overindulgence after an attempt
of abstinence. If a person should revert back to substance
abuse, the CUES facilitates a space with medical personnel
on hand should emergency care be needed. Furthermore,
individuals in recovery are also given a sense of purpose in
facilitating conversations and providing encouragement for
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PWIDs which is an impetus to remain in recovery.
Early Education: Although the government continues to
propose and introduce new initiatives focusing on increased
early education for new and future healthcare professionals,
the nation as a whole continues to fall short of reaching the
educational goal. Looking forward, the integration of
healthcare students into the CUES would be paramount in
buffering the opioid epidemic. The introduction of
healthcare professionals into the CUES would be beneficial
for all parties involved.
Healthcare institutions: The CUES would serve
as an opportunity for healthcare institutions to
show their continued commitment towards the
opioid crisis and towards some of the most
underserved populations of our country.
Students: Involvement early on in their career
equips them with the necessary practical
experience and much needed skills in dealing with
the opioid epidemic, in addition to making them
more adept with dealing with the underserved
populations.
CUES facilities: In addition to providing
voluntary services to the facility from trained
healthcare professionals, it will also help
destigmatize the public’s perceptions of these sites
since the CUES could show the fact that they are
also focusing on educating our young health
professionals early on in their careers.
4.4. Discussion
Nevertheless, the model safe injection facility compounded
with the additional services suggested makes the CUESs a
strong viable option for Philadelphia. Fentanyl screening
provides a sharp cognizance for safety by showing PWID
the risks of injecting elicited drugs. From the perspective of
the healthcare personnel and students training in the
healthcare system, the CUES provides first-hand exposure to
the opioid epidemic and gain first-hand experience in
attending to PWID in wound care services and also in
counseling. The interactions with PWID helps students form
one-on-one relationship and are able to help with PWID feel
they are ready. Equipping young healthcare professionals
with the necessary skills in dealing with the opioid crisis will
be paramount looking forward, as the opioid crisis continues
to climb. Furthermore, offering Hep-C/HIV screenings is a
preventative means of encouraging PWIDs to seek treatment
early before the progression to the viral latent stages.
Logistically, the combination of the needle exchange
program with the CUES could help clean the area of needles
and reduce the number of blood-borne diseases and skin and
soft tissue infections. As a result, these measures could
effectively reduce the overall healthcare costs.  Having
healthcare personnel on hand compounded with educative
Narcan distribution may reduce number of fatal overdoses
and hospitalizations. Providing an informational center run
by people in recovery provides a safe space for PWIDs to
openly discuss their concerns and seek while also giving
those in recover a sense of purpose and impetus to remain in
recovery. Thus, the implementation of the CUES offers
various dynamics that could curb the ever-increasing opioid
crisis in Philadelphia.
However, we witness the exact same criticisms against Insite
resurfacing upon the installation of a CUES. However, in the
aforementioned Insite section, we had addressed the
opponents’ concerns listed as five major critiques. Thus,
rather than reiterating those responses, we stress that the
criticisms are repudiated conceptually, psychologically, and
statistically [74].
4.4.1. Harms Reduced/Benefits Reaped: Projected Estimates
CUES models after Insite which has reduced significant
harms on both individual patient and community levels. It is
projected that in Philadelphia, on a yearly basis, there will be
between 3 and 48 averted cases of HIV infection, 15 to 213
averted Hepatitis C cases, and 24 to 76 overdose-related
deaths to be prevented. From an economic standpoint, with
the installment of a CUES, a great possible saving is
expected. Officials in Philadelphia estimate that the CUES
could reduce costs related to hospitalization for skin and soft
tissue infections between $1,512,356 and $1,868,205 per
year. Again, they also estimate that the total value of
overdose deaths averted is between $12,462,213 and
$74,773,267 annually, which includes a reduction of
$123,776 from ambulance costs; $280,683 in savings from a
reduction in hospital emergency department utilization and
$247,971 in savings from reduced hospitalizations [8]. Also,
as mentioned earlier, the value of overdose deaths averted
could reach between $12.5 and $74.8 million annually,
reduce ambulance costs by $123,776 per year, and save
$271,971 in hospital costs annually for PWID [74]. Also,
reduction in skin infections could save the healthcare system
between $1.5 and $1.9 million annually. Of course, it is
difficult to provide an accurate assessment on the costs
compared to benefits. But the primary variable is that we are
not certain how many individuals would utilize the CUES.
After a few months of data collection following the
establishment of the site, an accurate cost/benefit analysis
can be produced by reference to financial index.
4.4.2. The CUES’s Emphasis of Community Education
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Philadelphia’s CUES program should have an added
emphasis on education which is aimed not only at the users
that these sites serve but also the members of the
surrounding community. The officials from Canada’s Insite,
healthcare personnel, law enforcement members,
international SIF representatives, and members in the
community will convene in a series of forums exchanging
ideas, addressing concerns, etc. Once opened, PWID would
learn how to use their drugs in the safest ways possible, how
to properly discard needles, and how to administer naloxone
in the event of an overdose. The education will reduce the
number of overdoses, mitigate the transmission of infectious
diseases such as HIV and Hepatitis C, lower the amount of
social disorder in the surrounding neighborhoods, and lower
the financial and resource burden on the healthcare system.
Also, there will be continual community education with a
focus on why safe injection sites would have a positive
impact on the area based on principles from the harm
reduction theory which is addressed in detail next [74].
5. HARM REDUCTION AS PRACTICAL ETHICAL
JUSTIFICATION
The driving ethical force behind the push for CUESs to be
made available as a viable option for PWID is its potential to
be used under the harm reduction idea. Harm reduction is an
approach focused on minimizing the negative results that go
hand-in-hand with drug abuse [75] [76]. Harm reduction
techniques have both a medical and ethical impact on the
individual and society as a whole.  Harm reduction
techniques accept the individuals as they are, while also
tailoring that person’s treatment to fit his or her needs [77].
Furthermore, there are certain principles that are
quintessential to an understanding of harm reduction, as
listed by the Harm Reduction Coalition:
Accepts, for better and or worse, that licit and
illicit drug use is part of our world and chooses to
work to minimize its harmful effects rather than
simply ignore or condemn them.
Understands drug use as a complex, multi-faceted
phenomenon that encompasses a continuum of
behaviors from severe abuse to total abstinence and
acknowledges that some ways of using drugs are
clearly safer than others.
Establishes quality of individual and community
life and well-being–not necessarily cessation of all
drug use–as the criteria for successful interventions
and policies.
Calls for the non-judgmental, non-coercive
provision of services and resources to people who
use drugs and the communities in which they live
in order to assist them in reducing attendant harm.
Ensures that drug users and those with a history of
drug use routinely have a real voice in the creation
of programs and policies designed to serve them.
Affirms drugs users themselves as the primary
agents of reducing the harms of their drug use and
seeks to empower users to share information and
support each other in strategies which meet their
actual conditions of use.
Recognizes that the realities of poverty, class,
racism, social isolation, past trauma, sex-based
discrimination and other social inequalities affect
both people’s vulnerability to and capacity for
effectively dealing with drug-related harm.
Does not attempt to minimize or ignore the real
and tragic harm and danger associated with licit
and illicit drug use [75].
The CUES’ ability to allow PWID to have a safe
environment to inject drugs gives itself the potential to be
used as a harm reduction agent in and of itself.  Furthermore,
many individuals who die from opiate overdoses like heroin
did not receive necessary medical treatment in time to save
them; allowing PWIDs’ access to the CUES could possibly
save many preventable deaths. If we, as a society, value
human life as sacred, we must find a way to prevent these
deaths. The CUES program, like Insite in Vancouver,
supervised by trained medical personnel as a harm reduction
agent could present a viable alternative to address the
growing heroin addiction epidemic and save thousands of
lives. The heroin epidemic is growing, fatal overdoses are
increasing, and people are becoming more and more
frustrated by legal and political barriers to new forms of
treatment being put in place to stop this problem. As shown
above, SIFs like Insite have been shown to decrease heroin
abuse, disease, and mortality rate in Canada and Europe. In
the United States, overdoses have led to 45,000 opioid
overdose deaths in a 12-month period that ended in
September 2017. This number is unacceptable by any
standards [78]. Therefore, the harm reduction initiatives like
Insite and a CUES must be introduced.
6. RECOMMENDATIONS
While the CUES is a viable option for the city of
Philadelphia, it is understood that logistic, legal, and
financial implications may arise as a result. In an effort to
mitigate such implications, this article proposes the
following strategic recommendations.
In accordance with the City of Philadelphia’s report on
exploratory site visits for CUESs, this article motions to
convene with interested stakeholders, work with elected
officials to conduct community education and engagement
activities at the citywide and neighborhood levels and
identify funding sources [79].
In addressing the academic, medical, and legal affiliations
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with CUESs, we propose that the Mayor of Philadelphia
calls for a summit between the local universities, medical
schools, local medical residency programs, hospitals, law
enforcement in addition to representatives from the
communities and rehabilitation centers. This would create an
environment in which the healthcare, public health, and legal
communities may work cohesively to take the next step in
implementing these sites, and further address the opioid
crisis.
Additionally, we call for the creation of national principles
that include universal screenings, access to medications and
continuing long term patient care places further emphasis on
the opioid epidemic as a healthcare issue. It is believed that,
once private users recognize these standards and create
financial incentives to meet them, the rest of the health care
system will follow [80].
Also, the federal government should create regulations on
opioid prescribing. It creates a system which forces
healthcare to actively consider methods in the best interests
of their patients in terms of pain management. A study from
the Journal of the American Medical Association found that
NSAIDs are more effective in treating pain than opioid-
based medications [81]. In 2016, the Surgeon General’s
report stated that 10 percent of 21 million Americans with
substance-use disorders will receive treatment [80]. Even so,
there are no standards of care for treating addiction when it
is a complex disorder that requires a multi-pronged
approach. The creation of a protocol to treat those with
substance use disorder within healthcare systems provides a
mentality of treating addiction as a disease and giving people
the appropriate care they need. It not only allows physicians
to reexamine their methodology of pain management but
also educates and trains future physicians about the epidemic
and how to properly care for individuals with substance
abuse disorder.
Most importantly, widespread education and advocacy is
important for creating an informed community which shapes
the mindset regarding one’s approach to the opioid epidemic
as a whole. In the face of this public health emergency, it is
easy to first accuse those who are responsible. However, it is
the vulnerable populations and ethnicities who are often
accused leading to incarcerations and stigmatism. The opioid
effects compounded with the incarcerations have broken
individuals and their families leaving them subject to
criticism and pushed to the wayside. Therefore,
acknowledging that the opioid epidemic is a multi-faceted
systemic issue and providing education and awareness is a
critical component to the public understanding of the harm
reduction theory and taking the necessary steps to address
this crisis. Nevertheless, the recommendations with the
additional services proposed could lay the foundations to
make Comprehensive User Engagement Sites an effective
paradigm for Philadelphia.
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